BioHealth News Archive
Innara Health joins MedTech Innovator accelerator – Kansas City Business Journal
Olathe-based Innara Health is setting its sights on international expansion, and its acceptance into a national accelerator program could help that goal come to…
Read More
Six Veteran-Owned Life Science Companies to Know in the BioHealth Capital Region · BioBuzz
Across Maryland and the BioHealth Capital Region (BHCR), state-level support for veteran-owned and operated life science businesses is strong. This is evidenced by the…
Read More
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate | Emergent BioSolutions Inc.
GAITHERSBURG, Md., July 06, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a five-year manufacturing services agreement with Janssen Pharmaceuticals, Inc., one…
Read More
Five BioHealth Capital Region Companies Make List of Largest COVID-19 Government Contracts · BioBuzz
At BioBuzz, we’ve been chronicling the BioHealth Capital Region’s contributions to the battle against the coronavirus pandemic. We’ve covered BHCR companies developing vaccine candidates…
Read More
Baltimore firm Protaryx making medical devices for heart surgery raises $8M – Baltimore Business Journal
The UMB-born startup was co-founded by cardiac surgery chief Dr. James Gammie, who was previously involved with another company that was acquired in 2017…
Read More
Baltimore biotech company PathSensors will be acquired – Technical.ly Baltimore
Inner Harbor-based biotech company PathSensors will be acquired by global security screening and threat detection company Smiths Detection, the companies announced this week. With…
Read More
BHI Client Gentian awarded up to NOK 8.0 million funding to develop a novel high-throughput COVID-19 antibody test
Gentian Diagnostics AS is pleased to announce that the Research Council of Norway (Norges Forskningsråd) has awarded Gentian up to NOK 8.0 million of…
Read More
COVID-19 Drug & Vaccine Candidate Tracker | GEN
Welcome to GEN’s COVID-19 DRUG & VACCINE CANDIDATE TRACKER website. Total Drug & Vaccine Candidates: 237 (as of June 8) The goal of this resource…
Read More
Mark your calendars now! 5th Annual Women Building Bio (Interactive Virtual Conference)
September 12, 2020 Special Guests Including: Dr. Michele McMurry-Hearth President and CEO, Biotechnology Innovation Organization (BIO) {iframe}https://ym-virginiabio.informz.net/informzdataservice/onlineversion/ind/bWFpbGluZ2luc3RhbmNlaWQ9OTQzNTc1NSZzdWJzY3JpYmVyaWQ9MTEwMzcyNjM5NA=={/iframe}
Read More
Biobuzz Directory – Altimmune Receives Award From U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID™ in Outpatients With Early COVID-19
GAITHERSBURG, Md., June 29, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it was awarded $4.7 million from…
Read More
Emergent Bio inks five-year deal with J&J for manufacture of COVID-19 vaccine (NYSE:EBS) | Seeking Alpha
Emergent BioSolutions (NYSE:EBS) has closed a five-year agreement with Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceuticals for large-scale drug substance manufacturing for J&J's SARS-CoV-2…
Read More
NYC Builds Bio | The City’s Premier Organization for Real Estate.
Across the country today, not just in Boston and San Francisco, in leading and emerging life science clusters, life sciences institutions and innovative companies…
Read More
ITI Enters into License Agreement with Ichor to Use Electroporation (EP) Delivery Technology in Phase I Study of DNA Vaccine Therapy, ITI-1001 – BioHealth Capital Region
ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms and Ichor Medical Systems (“Ichor”),…
Read More
The Life Sciences Report: Summer 2020 | Wilson Sonsini Goodrich & Rosati – JDSupra
The latest issue of The Life Sciences Report features an interview with Matthew J. Meyer, the firm's chief client corporate development officer, who has…
Read More